AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 22 min read$LGND

Reardon Andrew sold $46K of LGND

Reardon Andrew (CLO & Secretary) sold 200 shares of LIGAND PHARMACEUTICALS INC (LGND) at $230.41 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reardon Andrew
Published Jun 2, 2026, 10:22 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$LGND
Neutral
medium confidence
Mentioned
$LGND
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LGNDNeutralLow
01

Why it matters

No new operational or financial information is provided—only the disclosed sale and post-transaction holdings.

02

Market read

Traders may treat this as low-signal insider activity; any short-term price effect is likely sentiment/positioning rather than fundamentals.

03

What to watch

The dollar amount is small relative to typical institutional float, and 10b5-1 plans often run on fixed schedules, reducing interpretability.

Relevance 6/10Novelty 3/10Timing: Filed today; transaction dated 2026-06-01 (after-hours disclosure window).

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by an officer (CLO & Secretary) with a stated pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$LGNDNeutralMedium confidence
Context

Ligand Pharmaceuticals officer Andrew Reardon sold 200 shares in an open-market transaction disclosed via SEC Form 4 under a 10b5-1 plan.

Expected impact

Likely minimal; any reaction is more sentiment/positioning than a new fundamental catalyst.

Evidence & confidence

The filing is an ownership-change disclosure with no accompanying corporate event (earnings, trial result, deal, or guidance change) and explicitly notes a pre-arranged 10b5-1 plan.

Market effects

Sector

Limited read-through to biotech/therapeutics peers; this is company-specific insider activity without a broader sector trigger.

Regional

None expected beyond US small/mid-cap biotech sentiment.

Global

None expected.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may watch for follow-on sales or changes in selling cadence.

Key entities

  • issuer
    Ligand Pharmaceuticals Inc

    Subject of the SEC Form 4 insider transaction disclosure.

  • insider
    Andrew Reardon

    Officer (CLO & Secretary) who sold 200 shares under a 10b5-1 plan.

Read at source← All news

Related articles

AUG 8
$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

yahoo.com7 min
AUG 6
$LGNDMed

LIGAND PHARMACEUTICALS INC (LGND): Results of Operations and Financial Condition

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease_ex991.htm EX-99.1 Document Ligand Reports Second Quarter 2026 Financial Results Second quarter performance driven by strong year-over-year royalty revenue growth of 32% Raises Low End of 2026 Adjusted EPS Guidance; Revenue Guidance Unchanged Confer

SEC EDGAR 8-K6 min
JUL 14
$LGNDMedAI 9/10

XOMA Royalty Announces Closing of Its Acquisition by Ligand

XOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.

manilatimes.net2 min
JUL 14
$LGNDMedAI 9/10

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty for $39.00 per share in cash, totaling about $739 million equity value, plus one CVR per share tied to 75% of net litigation proceeds. The deal adds seven commercial products and 100+ development assets, expanding its portfolio to 200+ royalties. Expected EPS accretion: +$0.50 (2026) and +$1.50 (2027).

manilatimes.net3 min
JUL 14
$LGNDMed

LIGAND PHARMACEUTICALS INC (LGND): Completion of Acquisition or Disposition of Assets

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. 8-K LIGAND PHARMACEUTICALS INC false 0000886163 0000886163 2026-07-14 2026-07-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest

SEC EDGAR 8-K4 min
JUL 13
$CECOMed

5 Stock Setups Where Wall Street Sees the Most Upside Right Now

The article lists five “upside” stock calls from Wall Street. JPMorgan initiated CECO Environmental (CECO) with a $130 target, citing AI data center demand and Thermon. It also targets PRM at $50. Goldman upgraded Toast (TOST) to Buy at $36. BofA raised Ligand (LGND) target to $388. Revolution Medicines (RVMD) reported Phase 3 pancreatic cancer results for daraxonrasib, with median OS 13.2 vs 6.7 months.

yahoo.com7 min